Prolia (Denosumab) - Therapy for Prevention and Treatment of Osteoporosis - Clinical Trials Arena
JHL Becomes Eden And Announces Denosumab Progress :: Generics Bulletin
10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension - The Lancet Diabetes & Endocrinology
RESULTS - Denosumab (Prolia) - NCBI Bookshelf
Denosumab for the treatment of osteoporosis: A systematic literature review | Reumatología Clínica
Denosumab for the treatment of osteoporosis: A systematic literature review | Reumatología Clínica
Denosumab Versus Zoledronic Acid in the Prevention of Skeletal-related Events in Vulnerable Cancer Patients: A Meta-analysis of Randomized, Controlled Trials - Clinical Therapeutics
A Review on the Role of Denosumab in Fracture Prevention | DDDT
Osteoporosis: Addressing the Unmet Need | American Pharmaceutical Review - The Review of American Pharmaceutical Business & Technology
Safety, Efficacy, & Side Effects | Prolia® (denosumab)
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis | NEJM
Romosozumab Treatment in Postmenopausal Women with Osteoporosis | NEJM
Prolia (Denosumab) - Therapy for Prevention and Treatment of Osteoporosis - Clinical Trials Arena
Denosumab
Frontiers | Pros and Cons of Denosumab Treatment for Osteoporosis and Implication for RANKL Aptamer Therapy | Cell and Developmental Biology
Denosumab for the Reduction of Bone Loss in Postmenopausal Osteoporosis: A Review - Clinical Therapeutics
EVENITY® (romosozumab-aqqg) vs Placebo Study Design
Clinical effects of switching from minodronate to denosumab treatment in patients with postmenopausal osteoporosis: a retrospective study | BMC Women's Health | Full Text
Denosumab (Prolia) (Word, 331 KB)
Safety, Efficacy, & Side Effects | Prolia® (denosumab)
Two-year clinical outcome of denosumab treatment alone and in combination with teriparatide in Japanese treatment-naive postmenopausal osteoporotic women | Bone Research
